Xiaobin Wang
10 Papers
13 Citations
Xiaobin Wang is an academic researcher. The author has contributed to research in topics: Cancer research & Medicine. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation
Zecong Xiao,Tan Li,Xi Bao Zheng,Xiaobin Wang,Jing James Huang,Yong Wang,Xintao Shuai,Kangshun Zhu +7 more
TL;DR: In this paper , an antigen-capturing nanoplatform, whose surface was modified with mannose as a targeting ligand, was constructed for co-delivery tumorassociated antigens (TAAs) and m6A demethylases inhibitor (i.e., fat mass and obesity associated gene (FTO)) into TIDCs.
35
Nanodrug simultaneously regulates stromal extracellular matrix and glucose metabolism for effective immunotherapy against orthotopic pancreatic cancer
TL;DR: In this article , a pH-sensitive and mesothelin-targeting nanodrug incorporating C-X-C motif chemokine ligand 1 (CXCL1) siRNA and PI3K signaling inhibitor wortmannin (WT) was prepared.
19
CAR NK‐92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo
Manting Liu,Wensou Huang,Yongjian Guo,Yubo Zhou,Cheng Zhi,Jingwu Chen,Junping Li,Jinping He,Hui-Ming Lian,Jingwen Zhou,Xiaodie Ye,Yuling Hu,Hongyan Hu,Zhaoyuan Liu,Jing James Huang,Mingyue Cai,Xiaobin Wang,Jing Huang,Zhenfeng Zhang,Kangshun Zhu,Qi Zhao,Bihui Cao +21 more
TL;DR: The potent antitumor activities of DLL3‐CAR NK‐92 cells were observed in subcutaneous tumor models of SCLC and detections of obvious tumor‐infiltrations were detected in DLL2‐SCLC xenografts.
17
Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy.
Zecong Xiao,Yitong Tan,Yu-Jun Cai,Jinsheng Huang,Xiaobin Wang,Bo Li,Yong Wang,Xintao Shuai,Kangshun Zhu +8 more
TL;DR: In this paper , hyaluronidase (HAase), IL-12, and anti-PD-L1 antibody were co-delivered using pH and MMP-2 dual-sensitive polymer/calcium phosphate (CaP) hybrid nanocarrier.
16
Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy
Hongxi Wu,Yan Li,Guangjiang Shi,Shijia Du,Xiaobin Wang,Wanli Ye,Zixuan Zhang,Ya Chu,Shuqian Ma,Dajia Wang,Yuan Li,Zhen Chen,Lutz Birnbaumer,Zhu Wang,Yong Yang +14 more
TL;DR: In this paper , the interferon signaling pathway plays a critical role in modulating the efficacy and sensitivity of anti-PD-1 therapy against multiple tumor types, but the mechanisms are unclear.
13